Clinical Trial Market Research Reports & Industry Analysis
Clinical Trial Industry Research & Market Reports
-
Bone & Joint Health Supplements Market by Type (Vitamin D, Vitamin K, Calcium, Collagen, Omega 3-Fatty Acid, Glucosamine-Chondroitin), Distribution Channels, Form (Tablets, Capsules, Liquid, Powder), Target Consumers and Region - Global Forecast to 2027
... global bone & joint health supplements market is estimated to be valued at USD 11.7 billion in 2022. It is projected to reach USD 17.6 billion by 2027, recording a CAGR of 8.5% during the ... Read More
-
Global Cognition and Memory Enhancement Market Size study, by Product & Service (Cognition & Memory-enhancing Drugs, Brain-boosting Nutraceuticals, Cognitive Assessment & Training Solutions) and Regional Forecasts 2022-2028
... at approximately USD 23 billion in 2021 and is anticipated to grow with a healthy growth rate of more than 10% over the forecast period 2022-2028. Cognitive and memory enhancer pharmaceuticals are supplements or medications ... Read More
-
Global AI-based Clinical Trials Solution Provider Market Size study, By Clinical Trial Phase (Phase-I, Phase-II, Phase-III), By Application (Oncology, Cardiovascular Diseases, Neurological Diseases or Conditions, Infectious Diseases, Others), By End-use (Pharmaceutical Companies, Academia, Others), and Regional Forecasts 2022-2028
... Regional Forecasts 2022-2028 Global AI-based Clinical Trials Solution Provider Market is valued at approximately USD XX million in 2021 and is anticipated to grow with a healthy growth rate of more than XX% over the ... Read More
-
Healthcare Smart Contracts Market Size, Share & Trends Analysis Report By Blockchain Type (Ethereum, Hyperledger Fabric), By Application (Clinical Trials, Supply Chain Management), By End-use, By Region, And Segment Forecasts, 2022 - 2030
... is expected to expand at a CAGR of 20.5% from 2022 to 2030. Key benefits offered by technology such as decentralized management, data provenance, robust data, traceable data drives the market. Increasing businesses demand the ... Read More
-
Global Regulatory Affairs Outsourcing Market Size study, by Services (Regulatory Consulting, Legal Representation, Regulatory Writing & Publishing, Product Registration & Clinical Trial Applications, Other Services) by Company Size (Small, Medium, Large) by Category (Drugs, Generics, Innovators, Biologics, Biotech, ATMPs, Biosimilars, Medical devices, Therapeutic, Diagnostic) by Indication (Oncology, Neurology, Cardiology, Immunology, Others) by Stage (Preclinical, Clinical, PMA (Post Market Authorization)) by End-use (Medical Device Companies, Pharmaceutical Companies, Biotechnology Companies) and Regional Forecasts 2022-2028
... Innovators, Biologics, Biotech, ATMPs, Biosimilars, Medical devices, Therapeutic, Diagnostic) by Indication (Oncology, Neurology, Cardiology, Immunology, Others) by Stage (Preclinical, Clinical, PMA (Post Market Authorization)) by End-use (Medical Device Companies, Pharmaceutical Companies, Biotechnology Companies) and Regional ... Read More
-
United States Human Vaccines Market Size, Share, Top 45 Human Vaccines Brand In-depth Analysis, Emerging Trends, Current Analysis, Growth, Demand, Opportunity, and Forecast 2022 – 2028
... market is poised to grow by US$ 31,517 million by 2028, accelerating at a CAGR of 7% during the forecast period. The prominent factors that are expected to contribute to the growth of the United ... Read More
-
Major Depressive Disorder Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
... there will be more than 18 million diagnosed prevalent cases of MDD across 16 pharmaceutical markets. There are four leading marketed drugs for the treatment of MDD, Otsuka Pharmaceutical is a key player in the ... Read More
-
Rosacea Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
... than 47 million diagnosed prevalent cases of rosacea across 16 pharmaceutical markets. There are 10 FDA approved branded marketed drugs for the treatment of rosacea. The rosacea pipeline consists of over 32 pharmaceuticals spanning all ... Read More
-
Clinical Trials Market Size By Phases (Phase I, Phase II, Phase III, Phase IV), By Study Design (Interventional Study, Observational Study, Expanded Access Study), By Therapeutic Area (Autoimmune Disease, Oncology, Cardiology, Infectious Disease, Dermatology, Ophthalmology) Industry Analysis Report, Regional Outlook, Application Potential, Covid-19 Impact Analysis, Price Trends, Competitive Market Share & Forecast, 2022 - 2030
... Industry Analysis Report, Regional Outlook, Application Potential, Covid-19 Impact Analysis, Price Trends, Competitive Market Share & Forecast, 2022 - 2030 The clinical trials market is expected to witness substantial growth by the end of 2030 ... Read More
-
Aicardi-Goutieres Syndrome Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
... than 4,000 prevalent cases of AGS each in 2022 across the 16 countries covered in GlobalData’s epidemiology forecast. No FDA-approved marketed drugs are available for AGS, only symptomatic treatment is indicated for disease management. The ... Read More
-
Clinical Trial Imaging Market Analysis and Forecast to 2031: By Product & Service (Services, Software), Modality (Computed Tomography, Magnetic Resonance Imaging, Ultrasound, Positron Emission Tomography, X-ray, Endocardiography), Therapeutic Area (Oncology, Infectious Diseases, Neurology, CVS, Endocrinology, Immunological Disorder), End User (Pharmaceutical Companies, Biotechnology Companies, Medical Device Manufacturer, Contract Research Organizations, Academic & Government Research Institutes), and Region
... Immunological Disorder), End User (Pharmaceutical Companies, Biotechnology Companies, Medical Device Manufacturer, Contract Research Organizations, Academic & Government Research Institutes), and Region The global clinical trial imaging market was valued at USD 1.2 billion in 2021 ... Read More
-
2022 Global Forecast for Angioimmunoblastic T-Cell Lymphoma (Ailt) Treatment Market (2023-2028 Outlook)-High Tech & Emerging Markets Report
... over 50 countries. The global market is expected to increase from USD xx billion in 2022 to USD xx billion by 2028, at a CAGR of xx% from 2023 to 2028. Estimates on equipment or ... Read More
-
Cardiomyopathies Market Size and Trend Report including Epidemiology and Pipeline Analysis, Competitor Assessment, Unmet Needs, Clinical Trial Strategies and Forecast, 2021-2031
... fills with substances that do not belong Dilated CM, Hypertrophic CM (Obstructive/Non-Obstructive), RCM, ACM Symptoms: Shortness of breath/trouble breathing, fatigue, swelling in the ankles, feet, legs, abdomen and veins, dizziness, light-headedness, fainting during physical activity, ... Read More
-
Computational Biology Market By Application (Cellular & Biological Simulation, Drug Discovery & Disease Modelling, Preclinical Drug Development, Clinical Trials, Human Body Simulation Software), By Services (In-house, Contract), By End Use (Academics & Research, Commercial): Global Opportunity Analysis and Industry Forecast, 2021-2031
... Opportunity Analysis and Industry Forecast, 2021-2031 The global computational biology market was valued at $5,493.2 million in 2021, and is projected to reach $31,477.1 million by 2031, registering a CAGR of 19.5% from 2022 to ... Read More
-
Global Rare Disease Drugs Market (2022 Edition) – Analysis By Drug Type, Therapeutic Area, Patients, Route of Administration, Distribution Channel, By Region, By Country (2022 Edition): Market Insights, and Forecast with Impact of COVID-19 (2022-2027)
... Executive Summary According to Azoth Analytics research report, the Global Rare Disease Drugs was valued at USD 147.12 Billion in the year 2021. The increasing focus on research activities and the development of novel therapeutic ... Read More
-
Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update
... 'Neuropeptide Y Receptor Type 2 - Drugs In Development, 2022'; Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R) pipeline Target constitutes close to 5 molecules. Out of which approximately 5 molecules are developed ... Read More
-
Gamma-Aminobutyric Acid Receptor Subunit Alpha 2 (GABA(A) Receptor Subunit Alpha 2 or GABRA2) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update
... Subunit Alpha 2 (GABA(A) Receptor Subunit Alpha 2 or GABRA2) - Gamma-aminobutyric acid A receptor, alpha 2 or GABRA2 is a protein encoded by the GABRA2 gene. GABRA2 are ligand-gated chloride channels and are activated ... Read More
-
5-Hydroxytryptamine Receptor 2B (5 HT2B or Serotonin Receptor 2B or HTR2B) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update
... or Serotonin Receptor 2B or HTR2B) - 5-Hydroxytryptamine receptor 2B (5-HT2B) or serotonin receptor 2B is a protein encoded by the HTR2B gene. It plays a role in the regulation of behavior, including impulsive behavior. ... Read More
-
5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update
... the recently published report '5-Hydroxytryptamine Receptor 7 - Drugs In Development, 2022'; 5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) pipeline Target constitutes close to 16 molecules. Out of ... Read More
-
Biologics Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)
... registering a CAGR of 9.22% during the forecast period, 2022-2027. With the growing COVID-19 burden, there has been a huge demand for biologics during the pandemic, which may drive the market growth. For instance, in ... Read More
-
Metabotropic Glutamate Receptor 1 (GPRC1A or MGLUR1 or GRM1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update
... or GRM1) - Metabotropic glutamate receptor 1 (mGluR1) is a protein encoded by GRM1. It activates a phosphatidylinositol-calcium second messenger system. It participates in the central action of glutamate in the CNS, such as long-term ... Read More
-
Metabotropic Glutamate Receptor 7 (GPRC1G or MGLUR7 or GRM7) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update
... Glutamate Receptor 7 - Drugs In Development, 2022'; Metabotropic Glutamate Receptor 7 (GPRC1G or MGLUR7 or GRM7) pipeline Target constitutes close to 7 molecules. Out of which approximately 5 molecules are developed by companies and ... Read More
-
Neuronal Acetylcholine Receptor Subunit Alpha 4 (CHRNA4) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update
... constitutes close to 5 molecules. Out of which approximately 4 molecules are developed by companies and remaining by the universities/institutes. The latest report Neuronal Acetylcholine Receptor Subunit Alpha 4 - Drugs In Development, 2022, outlays ... Read More
-
Gastric and Gastroesophageal Junction Adenocarcinoma Market Size and Trend Report including Epidemiology, Disease Management, Pipeline Analysis, Competitor Assessment, Unmet Needs, Clinical Trial Strategies and Forecast, 2019-2029
... fifth most common form of cancer: The standard of care in the first-line for both HER2-positive and -negative patients is now changing following the approvals of Opdivo in combination with chemotherapy for HER2-negative patients across ... Read More
-
Neuroendocrine Tumors Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
... of Neuroendocrine tumors will reach to 689,000 cases across the 16 countries covered in GlobalData’s epidemiology forecast. There are eight leading marketed drugs for the treatment of Neuroendocrine tumors. Pfizer, Novartis, and Hutchison are key ... Read More
Research Assistance
